Scale -

  • Quarterly Revenue is 570 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • Ebitda is 147 Rs Cr; Annual Decline is -24 %
  • PBT is 74.53 Rs Cr; Annual Decline is -23 %
  • PAT is 95.65 Rs Cr; Annual Decline is -19 %

Profitability -

  • PBDIT Margin is 8.13 %; Annual Decline is -23 %; in Bottom Quartile
  • PAT Margin is 5.29 %; Annual Decline is -19 %

Return -

  • Asset Turnover is 97 %; in Top Quartile; Continuous Decline over 3 years
  • ROCE is 7.64 %; Annual Decline is -40 %; Continuous Decline over 3 years; 5 Year CAGR is -21 %
  • ROA is 4.9 %; Annual Decline is -26 %; Continuous Decline over 3 years; 5 Year CAGR is -15 %
  • ROE is 7.61 %; Annual Decline is -25 %; Continuous Decline over 3 years; 5 Year CAGR is -19 %

Efficiency -

  • Current Ratio is 2.37; Continuous Growth over 3 years
  • Quick Ratio is 1.82; Continuous Growth over 3 years
  • Inventory Turnover Ratio is 6.32; in Top Quartile

Solvancy -

  • Debt/Equity is 0.16; Annual Growth is 129 %; Continuous Growth over 3 years; 5 Year CAGR is 52 %
  • Long term Debt is 134 Rs Cr; Annual Growth is 419 %; Continuous Growth over 3 years; 5 Year CAGR is 217 %
  • Total Debt is 195 Rs Cr; Annual Growth is 145 %; Continuous Growth over 3 years; 5 Year CAGR is 80 %
  • Contingent Liabilities is 341 Rs Cr; Annual Growth is 804 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 102 %

Quality -

  • Operating cashflow/ebitda is 22 %; Annual Growth is 33 %; in Bottom Quartile
  • Operating cashflow/PAT is 34 %; Annual Growth is 26 %
  • Current Tax/PAT is 17 %; Annual Decline is -39 %; Continuous Decline over 3 years
  • Change in Inventories/Total Expenses is 0 %; Annual Growth is 96 %
  • Exceptional Items/PBT is 22 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Morepen Laboratories Q2 Revenue Rises 81% To Rs 755 Crore As CDMO Business Scales Up
Read More
  • Past/current
Why is Morepen Labs share price falling? Stock slips 5% after results
Read More
  • Past/current
173% Stock Return, 27% Profit Growth: What's Driving Morepen Laboratories Ltd's Multibagger Rerating?
Read More
  • Past/current
Healthcare Stock Signals Bullish Momentum After Forming a Rounding Bottom Pattern
Read More
  • Past/current
Morepen Hits Record Q2FY27 Revenue Of Rs. 755 Cr; Driven By CDMO Momentum, EBITDA Surges 273% To Rs. 132 Cr In Q2FY27 And Rs. 220 Cr. In H1FY27
Read More
  • Past/current
Morepen Laboratories Delivers Record Q2, H1 FY27 Performance, With CDMO And Exports Driving Strong Growth
Read More
  • Past/current
Morepen Laboratories Limited Reports Unaudited Consolidated and Standalone Financial Results for Q2 and H1 FY 2026-27
Read More
  • Past/current
Morepen Laboratories reports record Q2 2026 revenue of Rs. 755 Cr with EBITDA soaring by 273%
Read More
  • Past/current
Morepen Laboratories reports record revenue and earnings for Q2 and H1 FY27, achieving Rs. 755 Cr quarterly revenue
Read More
  • Past/current
Morepen Labs Q2 Profit Jumps to Rs 89 Cr, Revenue Soars
Read More
  • Past/current
Morepen Labs Q2 Results: Net Profit More Than Doubles To Rs 89 Crore, Revenue Jumps 81% YoY
Read More
  • Past/current
Morepen Labs Q2FY27 Results: Net profit rises 117% YoY to ?89 crore
Read More
  • Past/current
Morepen Q2: revenue up 81% YoY to ?755 Cr as CDMO momentum drives net profit to ?89 Cr
Read More
  • Past/current
?Morepen Laboratories
Read More
  • Past/current